GlassScriptPhysician profile
Stephen B Whiteside
NPI 1184610131
$2,274.25
in general payments reported to CMS, 2019-2025
11 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $152 · 2021: $306 · 2022: $354 · 2023: $461 · 2024: $398 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,341.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,251.62 | 2022-2025 | Wavelight Refractive Suite, Wavelight Ex500 Excimer Laser, Contoura Vision |
| Johnson & Johnson Surgical Vision, INC. | $280.27 | 2020-2022 | |
| Heidelberg Engineering, INC. | $184.27 | 2021 | |
| Genentech USA, INC. | $141.42 | 2022 | |
| Harrow Eye, LLC | $124.72 | 2023 | Iheezo |
| Mallinckrodt Enterprises LLC | $119.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $94.01 | 2020-2022 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2024 | |
| Astellas Pharma Global Development | $27.16 | 2025 | Izervay |
| Eyepoint US, INC. | $15.36 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Whiteside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.